FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1693-1694 December 4, 1997 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Bolla, M. PubMed Citation

To the Editor: The article by Bolla et al. (July 31 issue)¹ has deficiencies, and the authors missed a golden opportunity to make a major scientific contribution. First, the study did not include a group of patients meeting the entry criteria who were treated only with goserelin for three years. Therefore, no valid conclusions can be reached about the preferred treatment for this group of patients. Comparisons with previous studies are of only limited value as compared with contemporaneous trials by the same investigators using the same standards.

Second, the patient group was heterogeneous, and the results were not stratified. . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kestin, L. L., Martinez, A. A., Stromberg, J. S., Edmundson, G. K., Gustafson, G. S., Brabbins, D. S., Chen, P. Y., Vicini, F. A. (2000). Matched-Pair Analysis of Conformal High-Dose-Rate Brachytherapy Boost Versus External-Beam Radiation Therapy Alone for Locally Advanced Prostate Cancer. JCO 18: 2869-2880 [Abstract] [Full Text]